Exciting times today.

May I ask a question of the experts on the board? (The implications of the findings from the long hauler trial are completely out of my league.)

Realize this trial was related to long covid- but wondering about if and how this might change future research and trials in other indications- particularly cancer. And specifically- the criteria for higher levels of CCR5 in cancer trial participants.

From the article: The researchers originally thought that blocking CCR5 with the antibody would dampen the activity of an overactive immune system after COVID-19 infection. “But we found just the opposite,” Yang said.

A while back, a loved one was found not to be eligible for the cancer trial - the result of not meeting the criteria of certain levels of CCR5. But am wondering if this new angle of the MOA might expand the thought/inclusions of who might benefit from leronlimab to those with low/no CCR5.

TIA!

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome